Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 2

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 2
---
    Amount  
     Capital  
    Deficit  
    Equity 

    Balances, December 31, 2023 
     28,609,814  
     -  
    $17,502,346  
    $(14,064,142) 
    $3,438,204 
  
    Issuance of common stock for cash, net 
     1,000,000  
     -  
     5,832,973  
     -  
     5,832,973 
  
    Net loss 
     -  
     -  
     -  
     (6,254,607) 
     (6,254,607)
  
    Balances, March 31, 2024 
     29,609,814  
     -  
     23,335,319  
     (20,318,749) 
     3,016,570 
  
    Net loss 
     -  
     -  
     -  
     (1,389,003) 
     (1,389,003)
  
    Balances, June 30, 2024 
     29,609,814  
     -  
     23,335,319  
     (21,707,752) 
     1,627,567 
  
    Net loss 
     -  
     -  
     -  
     (5,990,733) 
     (5,990,733)
  
    Stock-based compensation 
     -  
     -  
     4,805,240  
     -  
     4,805,240 
  
    Balances, September 30, 2024 
     29,609,814  
     -  
    $28,140,559  
    $(27,698,485) 
    $442,074 

    Balances, December 31, 2024 
     29,762,671  
     -  
    $31,239,895  
    $(30,596,858) 
    $643,037 
  
    Balance 
     29,762,671  
     -  
    $31,239,895  
    $(